Overview

Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)

Status:
Recruiting

Trial end date:
2025-07-31

Target enrollment:

Participant gender:

Summary

This is a single-arm, multicenter, phase 2 study of lenvatinib in combination with pembrolizumab (lenvatinib 20 mg/day + pembrolizumab 200mg q3weeks) in subjects with unresectable advanced or metastatic non-clear cell renal carcinoma who have not received any chemotherapy for advanced disease.

Phase:

Phase 2

Details

Lead Sponsor:

Washington University School of Medicine

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Lenvatinib
Pembrolizumab